ASH 2020 | Talquetamab: GPRC5D-CD3 bispecific antibody in R/R myeloma
Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, discusses the preliminary results of a Phase I study (NCT03399799) of talquetamab, a bispecific antibody that targets GPRC5D and CD3, in relapsed/refractory multiple myeloma patients. High GPRC5D expression is limited to myeloma cells, so talquetamab is able to induce their targeted T-cell killing. The first-in-human dose-escalation study was designed to determine the recommended Phase II dose of the treatment and its safety. The results show encouraging early efficacy results in a highly pretreated myeloma population and a manageable safety profile, with low rates of treatment-related neurotoxicity and high-grade cytokine release syndrome. A maximum tolerated dose has not yet been reached, and dose-escalation is ongoing. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
